Meeting
2023 ASCO Genitourinary Cancers Symposium
Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens.
Authors
Chris Labaki
The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
Chris Labaki , Ziad Bakouny , J Connor Wells , Kosuke Takemura , Renee Maria Saliby , Luis A Meza , Georges Gebrael , Camillo Porta , Jae-Lyun Lee , Naveen S. Basappa , Guillermo De Velasco , Rana R. McKay , Sumanta Monty Pal , Neeraj Agarwal , Frede Donskov , David A. Braun , Elizabeth Henske , Wanling Xie , Daniel Yick Chin Heng , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 654)
DOI
10.1200/JCO.2023.41.6_suppl.654
Abstract #
654
Poster Bd #
G5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2013 Genitourinary Cancers Symposium
Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.
First Author: Maristella Bianconi
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin
Poster
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
First Author: Sophie Laramee